153 related articles for article (PubMed ID: 38297484)
1. Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
Wiesen MHJ; Stemler J; Fietz C; Joisten C; Cornely OA; Verougstraete N; Streichert T; Müller C
Eur J Haematol; 2024 Jun; 112(6):879-888. PubMed ID: 38297484
[TBL] [Abstract][Full Text] [Related]
2. Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
Röllig C; Schliemann C; Ruhnke L; Fransecky L; Heydrich BN; Hanoun M; Noppeney R; Schäfer-Eckart K; Wendelin K; Mikesch JH; Middeke JM; Reimann M; Fiebig F; Zukunft S; Wermke M; Serve H; Platzbecker U; Müller-Tidow C; Baldus CD; Bornhäuser M
Br J Haematol; 2024 Jun; 204(6):2254-2258. PubMed ID: 38593353
[TBL] [Abstract][Full Text] [Related]
3. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
4. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
5. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Stone RM; Mandrekar SJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Lo-Coco F; Klisovic RB; Wei A; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Larson RA; Döhner H
N Engl J Med; 2017 Aug; 377(5):454-464. PubMed ID: 28644114
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
Sechaud R; Sinclair K; Grosch K; Ouatas T; Pathak D
Cancer Chemother Pharmacol; 2022 Jul; 90(1):19-27. PubMed ID: 35751657
[TBL] [Abstract][Full Text] [Related]
7. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
Arnán Sangerman M; Fernández Moreno A; García Quintana A; García-Vidal C; Olave Rubio MT; Del Mar Tormo Díaz M; Vendranas M; Rodriguez Macias G
Expert Rev Hematol; 2022 Mar; 15(3):203-214. PubMed ID: 35332831
[TBL] [Abstract][Full Text] [Related]
8. Multiplexed single-cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells.
Rörby E; Adolfsson J; Hultin E; Gustafsson T; Lotfi K; Cammenga J; Jönsson JI
Exp Hematol Oncol; 2021 Feb; 10(1):7. PubMed ID: 33531064
[TBL] [Abstract][Full Text] [Related]
9. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
Tollkuci E
J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838
[TBL] [Abstract][Full Text] [Related]
10. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X
BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study.
Menna P; Marchesi F; Cattaneo C; Candoni A; Delia M; Nadali G; Vatteroni A; Pasciolla C; Perrone S; Verga L; Armiento D; Del Principe MI; Fracchiolla NS; Salvatorelli E; Lupisella S; Terrenato I; Busca A; Minotti G; Pagano L
Clin Transl Sci; 2023 Oct; 16(10):1876-1885. PubMed ID: 37515369
[TBL] [Abstract][Full Text] [Related]
12. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia.
Tomlinson BK; Gallogly MM; Kane DM; Metheny L; Lazarus HM; William BM; Craig MD; Levis MJ; Cooper BW
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):226-233.e1. PubMed ID: 32085993
[TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.
Stein E; Xie J; Duchesneau E; Bhattacharyya S; Vudumula U; Ndife B; Bonifacio G; Guerin A; Li N; Joseph G
Pharmacoeconomics; 2019 Feb; 37(2):239-253. PubMed ID: 30382485
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
[TBL] [Abstract][Full Text] [Related]
16. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
17. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
Dutreix C; Munarini F; Lorenzo S; Roesel J; Wang Y
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1223-34. PubMed ID: 24085261
[TBL] [Abstract][Full Text] [Related]
18. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
19. Midostaurin: an emerging treatment for acute myeloid leukemia patients.
Gallogly MM; Lazarus HM
J Blood Med; 2016; 7():73-83. PubMed ID: 27186148
[TBL] [Abstract][Full Text] [Related]
20. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
